Loading
companiesCompany
pharma&
pharma& is a Vienna company that buys and markets established medicines, including the PARP inhibitor rucaparib (Rubraca), which it acquired from Clovis Oncology's bankruptcy in 2023.
Also called: pharmaand GmbHpharma& GmbHpharmaand
Overview
pharma& (pharmaand GmbH), based in Vienna, acquires and commercialises marketed medicines rather than developing new molecules. In oncology it bought rucaparib (Rubraca), the PARP inhibitor approved for BRCA-mutated ovarian and prostate cancer, from Clovis Oncology in 2023 after Clovis filed for bankruptcy, and it now holds the US and EU authorisations and runs the remaining trials and post-marketing commitments. It appears on OnCo as an FDA oncology applicant and a phase 3 trial sponsor on ClinicalTrials.gov.
Headquarters
Vienna, AT
Scorecard
All companies#183of 1244 companies, score 32
- approved products +6
- targets +4
- modalities +2
- regions +4
- 24-month regulatory events +2
- registry trials +14
1 approved, 0 in phase 3, 0 earlier, 2 targets, 49 registry studies. Formula on the scorecards page.
Type
Stage
Large private
Website
ApprovedSmall-molecule PARP inhibitor
Rucaparib · Rubraca
A PARP inhibitor for BRCA-mutated ovarian and prostate cancer whose original maker went bankrupt; still available, with a narrowed label.
Similar pages
- TrialATHENA-MONO / GOG-3020
Shares Clovis Oncology, Rucaparib, PARP, Ovarian cancer.
- PersonRuth Plummer
- TrialTRITON3
Shares Clovis Oncology, Rucaparib, PARP, Prostate cancer.
- TreatmentSenaparib (IMP4297)
Shares PARP, Ovarian cancer.
- PersonRobert L. Coleman
Shares PARP, Ovarian cancer.
- PersonAmit M. Oza
Shares PARP, Ovarian cancer.
- PersonJonathan A. Ledermann
Shares PARP, Ovarian cancer.
- Key paperTRITON2: rucaparib in men with metastatic castration-resistant prostate cancer harbouring a BRCA1 or BRCA2 alteration
Shares Clovis Oncology, Rucaparib, PARP, Prostate cancer.